CD274 and non-small cell lung carcinoma: ALI also represents a simple tool to predict immunotherapy efficacy in patients with advanced NSCLC treated with PD-L1 inhibitors alone, and the ALI score has a stronger predictive effect than NLR, the PD-L1 tumour proportion score and other biomarkers (Shiroyama et al., 2018; Mountzios et al., 2021).